Keywords
How to Cite
Abstract
Annually more than 250 thousand deaths from malignant diseases are registered in Russia and 8 million - in the world. The effectiveness of traditional methods of treatment, as well as of monoclonal antibodies and gene therapy is limited in the case of resistant forms of cancer and hard to reach tumors. Lactoferrin (LF) is a universal protein with anticancer activity and cross-species biocompatibility, which modulates the immune response and the redox/antioxidant system. Due to the ability to interact not only with specific receptors, but also with signaling and endocytosis receptors, TLR on various cell types, LF can overcome tissue barriers. The therapeutic efficacy of lactoferrin, its cleavage products, and synthetic peptides against various types of malignant proliferation was demonstrated with in vivo and in vitro models. The prospects of using LF as an adjuvant before chemotherapy and radiotherapy and as a carrier for gene therapy of cancer were experimentally demonstrated. However, the results of clinical studies are few and require further study.
References
Reale A., Vitiello A., Conciatori V. et al. Perspectives on immunotherapy via oncolytic viruses // Infect Agent Cancer. - 2019. - Vol. 14. - P. 5. - DOI: 10.1186/s13027-018-0218-1
Cao H., Xiao Z., Zhang Y et al. Dosimetric comparisons of different hypofractionated stereotactic radiotherapy techniques in treating intracranial tumors > 3 cm in longest diameter // J. Neurosurg. - 2019. - P. 1-9. - DOI: 10.3171/2018.12.JNS181578
Chea C., Miyauchi M., Inubushi T. et al. Molecular mechanism of inhibitory effects of bovine lactoferrin on the growth of oral squamous cell carcinoma // PLoS One. - 2018. - Vol. 13(1). - P. e0191683. - DOI: 10.1371/journal.pone.0191683
Lu Y., Zhang T.F., Shi Y. et al. PFR peptide, one of the antimicrobial peptides identified from the derivatives of lactoferrin, induces necrosis in leukemia cells // Sci. Rep. - 2016. - Vol. 6. - P. 20823. - DOI: 10.1038/srep20823
Gibbons J.A., Kanwar J.R., Kanwar R.K. Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer // BMC Cancer. - 2015. - Vol. 15. - P. 425. - DOI: 10.1186/s12885-015-1441-4
Levay P.F., Viljoen M. Lactoferrin: a general review // Haematologica. - 1995. - Vol. 80. - P. 252-267.
Siqueiros-Cendon T., Arévalo-Gallegos S., Iglesias-Figueroa B.F. et al. Immunomodulatory effects of lactoferrin // Acta Pharmacol Sin. - 2014. - Vol. 35(5). - P. 557-566. - DOI: 10.1038/aps.2013.200
Зорина В.Н., Зорин H.A. Белковые компоненты врожденного иммунитета в защите от патогенной инвазии // ЖМЭИ. - 2013. - Т. 3. - С. 111-117.
Actor J.K., Hwang S.A., Kruzel M.L. Lactoferrin as a natural immune modulator // Curr Pharm Des. - 2009. - Vol. 15(17). - P. 1956-1973.
Ebrahim F., Shankaranarayanan J.S., Kanwar J.R. et al. Identification of unprecedented anticancer properties of high molecular weight biomacromolecular complex containing bovine lactoferrin (HMW-bLf) // PLoS One. - 2014. - Vol. 9(9). - P. e106568. - DOI: 10.1371/journal.pone.0106568
Sharma S., Sinha M., Kaushik S. et al. C-lobe of lactoferrin: the whole story of the half-molecule // Biochem Res Int. - 2013. - Vol. 2013. - P. 271641. - DOI: 10.1155/2013/271641
Fischer R., Debbabi H., Blais A. et al. Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissues // Int. Immunopharmacol. - 2007. - Vol. 7(10). - P. 1387-1393. - DOI: 10.1016/j.intimp.2007.05.019
Wu J., Yang L., Liu G. et al. Isolation and purification of recombinant human lactoferrin (rhLF) from transgenic rice and its antibacterial activities // Wei Sheng Yan Jiu. - 2013. - Vol. 42(3). - P. 399-404.
Zimecki M., Artym J., Kociçba M. et al. The effect of carbohydrate moiety structure on the immunoregulatory activity of lactoferrin in vitro // Cell Mol Biol Lett. -2014. - Vol. 19(2). - P. 284-296. - DOI: 10.2478/s11658-014-0196-2
Legrand D., Elass E., Carpentier M., Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci. 2005 Nov;62(22):2549-59.
Nishimura Y, Homma-Takeda S., Kim H.S., Kakuta I. Radioprotection of mice by lactoferrin against irradiation with sublethal X-rays // J. Radiat. Res. - 2014. - Vol. 55(2). - P. 277-282. - DOI: 10.1093/jrr/rrt117
Mader J.S., Salsman J., Conrad D.M., Hoskin D.W. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines // Mol. Cancer Ther. - 2005. - Vol. 4(4). - P. 612-624. - DOI: 10.1158/1535-7163.MCT-04-0077
Hilchie A.L., Vale R., Zemlak T.S., Hoskin D.W. Generation of a hematologic malignancy-selective membranolytic peptide from the antimicrobial core (RRWQWR) of bovine lactoferricin // Exp. Mol. Pathol. - 2013. - Vol. 95(2). - P. 192-198. - DOI: 10.1016/j.yex-mp.2013.07.006
Vargas Casanova Y, Rodriguez Guerra J.A., Umana Pérez YA. et al. Antibacterial Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Cytotoxic Effect against MDA-MB-468 and MDA-MB-231 Breast Cancer Cell Lines // Molecules. - 2017. - Vol. 22(10). - pii: E1641. - DOI: 10.3390/molecules22101641
Solarte V.A., Conget P., Vernot J.P et al. A tetrameric peptide derived from bovine lactoferricin as a potential therapeutic tool for oral squamous cell carcinoma: A preclinical model // PLoS One. - 2017. - Vol. 12(3). - P. e0174707. - DOI: 10.1371/journal.pone.0174707
Kanwar J.R., Palmano K.P., Sun X. et al. ‘Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy // Immunol Cell Biol. - 2008. - Vol. 86(3). - P. 277-288. - DOI: 10.1038/sj.icb.7100163
Shimamura M., Yamamoto Y, Ashino H. et al. Bovine lactoferrin inhibits tumor-induced angiogenesis. Int J Cancer. 2004; 111(1):111-6. DOI: 10.1002/ijc.20187
Pereira C.S., Guedes J.P., Gonçalves M., Loureiro L., Castro L., Geros H., Rodrigues L.R., Côrte-Real M. Lactoferrin selectively triggers apoptosis in highly metastatic breast cancer cells through inhibition of plasmalemmal V-H+-ATPase. Oncotarget. 2016; 7(38):62144-62158. DOI: 10.18632/oncotarget.11394
Pan W.R., Chen P.W., Chen YL. et al. Bovine lactoferricin B induces apoptosis of human gastric cancer cell line AGS by inhibition of autophagy at a late stage // J. Dairy Sci. - 2013. - Vol. 96(12). - P. 7511-7520. - DOI: 10.3168/jds.2013-7285
Shaheduzzaman S., Vishwanath A., Furusato B. et al. Silencing of Lactotransferrin expression by methylation in prostate cancer progression // Cancer Biol. Ther. - 2007. - Vol. 6(7). - P. 1088-1095.
Tsuda H., Sekine K., Fujita K., Ligo M. Cancer prevention by bovine lactoferrin and underlying mechanisms - a review of experimental and clinical studies // Biochem Cell Biol. - 2002. - Vol. 80(1). - P. 131-136.
Eliassen L.T., Haug B.E., Berge G., Rekdal O. Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modifications // J. Pept. Sci. - 2003. - Vol. 9(8). - P. 510-517.
Lim L.Y., Koh P.Y., Somani S. et al. Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes // Nanomedicine. - 2015. - Vol. 11(6). - P. 1445-1454. - DOI: 10.1016/j.nano.2015.04.006
Wang J., Li Q., Ou Y et al. Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer // Arch Pharm Res. - 2011. - Vol. 34(6). - P. 987-995. - DOI: 10.1007/s12272-011-0616-z
Shen Z., Liu T., Li Y. et al. Fenton-Reaction-Acceleratable Magnetic Nanoparticles for Ferroptosis Therapy of Orthotopic Brain Tumors // CS Nano. - 2018. - Vol. 12(11). - P. 11355-11365. - DOI: 10.1021/acsnano.8b06201
Roseanu A., Florian P.E., Moisei M. et al. Liposomalization of lactoferrin enhanced its anti-tumoral effects on melanoma cells // Biometals. - 2010. - Vol. 23(3). - P. 485-492. - DOI: 10.1007/s10534-010-9312-6
Furlong S.J., Mader J.S., Hoskin D.W. Bovine lactoferricin induces caspase-independent apoptosis in human B-lymphoma cells and extends the survival of immune-deficient mice bearing B-lymphoma xenografts // Exp. Mol. Pathol. - 2010. - Vol. 88(3). - P. 371-375. - DOI: 10.1016/j.yexmp.2010.02.001
Eike L.M., Yang N., Rekdal 0., Sveinbj0rnsson B. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells // Oncotarget. - 2015. - Vol. 6(33). - P. 34910-34923. - DOI: 10.18632/oncotarget.5308
Camilio K.A., Berge G., Ravuri C.S., Rekdal O., Svein-bj0rnsson B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315 // Cancer Immunol Immunother. - 2014. - Vol. 63(6). - P. 601-613. - DOI: 10.1007/s00262-014-1540-0
Cheng W.D., Wold K.J., Bollinger L.B. et al. Supplementation With Lactoferrin and Lysozyme Ameliorates Environmental Enteric Dysfunction: A Double-Blind, Randomized, Placebo-Controlled Trial // Am J. Gastroenterol. - 2019. - Vol.114(4). - P. 671-678. - DOI: 10.14309/ajg.0000000000000170
Ramalingam S., Crawford J., Chang A. et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) // Ann Oncol. - 2013. - Vol. 24(11). - P. 2875-2880. - DOI: 10.1093/annonc/mdt371
Parikh P.M., Vaid A., Advani S.H. et al. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy // J. Clin. Oncol. -2011. - Vol. 29(31). - P. 4129-4136. - DOI: 10.1200/JCO.2010.34.4127
Hayes T.G., Falchook G.F., Varadhachary G.R. et al. Phase I trial of oral talactoferrin alfa in refractory solid tumors // Invest New Drugs. - 2006. - Vol. 24(3). - P. 233-240. - DOI: 10.1007/s10637-005-3690-6
Kozu T., Iinuma G., Ohashi Y et al. Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial // Cancer Prev. Res (Phila). - 2009. - Vol. 2(11). - P. 975-983. - DOI: 10.1158/1940-6207.CAPR-08-0208
Perez D., Sharples K.J., Broom R. et al. A randomised phase IIb trial to assess the efficacy of ReCharge ice cream in preventing chemotherapy-induced diarrhea // Support Care Cancer. - 2015. - Vol. 23(11). - P. 3307-3315. - DOI: 10.1007/s00520-015-2755-0
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019